The effectiveness of red-light therapy on myopia control depends on its direct effect: a mediation analysis
Chen Q, Wei H, Soh ZD, Zhu Q, Shao X, Xue C, Li H, Tao Y, Hu M, Cheng CY, Zhong H
Journal of translational medicine · 4 citations
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Independent funding
- Government
- National Natural Science Foundation of China-Yunnan Joint Fund
- Grants
- National Natural Science Foundation of China-Yunnan Joint Fund (82360212)
Based on 1 listed funder(s) and full-text disclosure statement.
Publication
- Published
- 2025-12-02 · J Transl Med · vol. 24 · issue 1 · p. 34
- Publisher
- BioMed Central
- Cited
- 2 citations · more than 82% of similar papers · 1.2× the field average
- References
- 44 works
- Access
- Open access (journal) · CC-BY-NC-ND
- Research areas
- Ophthalmology and Visual Impairment Studies · Retinopathy of Prematurity Studies · Retinal Diseases and Treatments
- Keywords
- Peripheral, Refraction, Mediation, Retinal, Randomized controlled trial, Choroid, Refractive error
- MeSH
- choroid, humans, myopia, refraction, ocular, treatment outcome, child, female, male, red light
11 authors
From CN, SG
- Qin ChenNanjing Medical University
- Hongyu WeiKunming Medical University; Singapore Eye Research Institute; First Affiliated Hospital of Kunming Medical University
- Zhi Da SohSingapore Eye Research Institute
- Qin ZhuYunnan University; Second People's Hospital of Yunnan Province
- Xian ShaoKunming Medical University; First Affiliated Hospital of Kunming Medical University
- Cancan XueSingapore Eye Research Institute
Abstract
PURPOSE: To investigate whether alterations in subfoveal choroidal thickness (SFCT) and peripheral retinal refraction mediate the efficacy of repeated low-level red-light (RLRL) therapy for myopia control. METHODS: We conducted a mediation analysis within a multicenter, randomized controlled trial. A total of 300 myopic children were included in this analysis. Participants in RLRL group wore single-vision spectacles (SVSs) and received red-light therapy twice daily for 12 months. The control group wore SVSs only, without any additional myopia-control intervention. Axial length (AL), spherical equivalent refraction (SER), SFCT and total refractive difference value (TRDV) were measured at baseline and at follow-up visits over 12 months. RESULTS: After 12 months, RLRL therapy significantly attenuated axial length and myopic shift in spherical equivalence compared with controls, accompanied by sustained increases in choroidal thickness and reductions in peripheral hyperopic defocus. Mediation analysis revealed that changes in choroidal thickness and peripheral refraction accounted for 24.83% and 6.79%, respectively, of the effect on axial length inhibition, and 28.79% and 5.97% of the effect on spherical equivalent control. The remaining effects were attributable to the direct impact of red-light (68.39% for axial length and 65.24% for spherical equivalence). Notably, choroidal thickening emerged as the predominant mediator within the first three months. CONCLUSIONS: RLRL therapy exerted a predominantly direct effect on myopia control, while changes in choroidal thickness and peripheral defocus partially mediated its effectiveness. TRIAL REGISTRATION: This trial was registered at the Chinese Clinical Trial Registry on January 30, 2021, with trial registration number: ChiCTR2100042836. https://www.chictr.org.cn/showprojEN.html?proj=120971 .
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC-ND).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.